Skip to content
EN
brief us →

Theranos, Inc.: leadership, investors, partners and proceedings, 2003–2026

Research data: Theranos, Inc.: leadership, investors, partners and proceedings, 2003–2026

This dataset contains the same public evidence as the dossier: participants, relationships, events, assertions and sources. Qualifications, replies and known outcomes are retained in JSON, JSONL and CSV. The scope and method explain which original records were accepted; this is not a copy of the original archive.

published
26 oct 2026
records as of
21 oct 2026
entities
87
sources
118
cite entities.csv

Downloads

As of 21 October 2026. 310 claims · 87 parties · 140 connections · 46 events · 118 sources

Scope and method

Covers Theranos, Inc. (formerly RealTime Cures, Inc.), its founder and officers, directors, investors, retail and health-care partners, laboratories, lenders, successor and assignee entities, regulators and the parties to its proceedings, from its founding in 2003 to records retrieved on October 21, 2026. It relies on the documents retained by one research collection, which its own records describe as incomplete; registry records for Theranos IP Company, Labrador Diagnostics and Haemanthus, the basis of Walgreens' 2018 claim and second sources for some board accounts were not retrieved, and documents outside the collection were not read.

Every statement and relationship extracted from the retained documents was read and given a recorded decision, and each public claim was compared with the exact passage of its source document. Allegations were searched for across all retained document text for responses and outcomes, which are kept beside each claim. Sources other than allowlisted official records of the SEC, federal and state courts, the Justice Department, CMS, HHS, the Arizona Attorney General, the U.S. Patent and Trademark Office, the Florida registry, Congress and other public bodies are identified by category only. Personal details such as ages, birth dates, home addresses, family members and prison identifiers are omitted, and private individuals who invested or sued are not named. The review was carried out by an AI editor and separate AI reviewer passes, without independent human review.

chronology

  1. Elizabeth Holmes founds Theranos c-id-founding-date c-ld-holmes-ceo
  2. RealTime Cures, Inc. is incorporated in Delaware c-id-incorporation
  3. RealTime Cures, Inc. becomes Theranos, Inc. c-id-incorporation
  4. Balwani guarantees a credit line and becomes President and Chief Operating Officer c-ld-balwani-guarantee c-ld-balwani-tenure
  5. Safeway signs a Master Purchase Agreement with Theranos for testing in its stores c-prt-safeway-2010
  6. Theranos files a Form D reporting $45 million sold of a $100 million offering c-fin-form-d-2010 c-ld-form-d-2010-persons
  7. Theranos and Walgreens sign their first Master Services Agreement c-wag-2010-agreement
  8. George Shultz joins the board c-ld-shultz-joins
  9. Walgreens and Theranos sign the 2012 Master Services Agreement, which provides for a $40 million convertible note c-wag-msa-2012 c-wag-note-wvc
  10. First Wellness Center opens in a Walgreens store in Phoenix c-wag-pilot
  11. Theranos announces the Wellness Center roll-out in Walgreens stores c-wag-pilot
  12. Class B shares give Holmes over 99 percent of the voting power c-fin-class-b
  13. FDA inspection of the Newark site ends with a Form 483 c-lab-fda-483
  14. CMS completes its survey of the Newark laboratory c-lab-cms-survey
  15. CMS notifies Theranos of immediate jeopardy in hematology c-lab-cms-survey
  16. Walgreens sends a notice of breach c-wag-breach-notice
  17. CMS proposes revoking the Newark laboratory certificate c-lab-cms-proposed
  18. Theranos announces Balwani's retirement and three new directors c-ld-may-2016 c-ld-balwani-tenure
  19. Walgreens terminates the agreement; it then closes the Wellness Centers c-wag-breach-notice
  20. CMS imposes sanctions including revocation of the Newark certificate c-lab-cms-sanctions
  21. Partner Fund investors sue in the Delaware Court of Chancery c-civ-delaware-suits
  22. Walgreen Co. sues Theranos in Delaware c-wag-suit-2016
  23. Indirect-investor class action is filed against Theranos, Holmes and Balwani c-civ-indirect-class
  24. Warmenhoven joins the board; the board of counselors is to be retired c-ld-dec-2016
  25. Theranos settles with CMS and the Arizona Attorney General c-lab-cms-settlement c-lab-az-ag
  26. Partner Fund suits settled; exchange offer to preferred holders c-civ-delaware-suits c-fin-form-d-2017
  27. Theranos announces its settlement with Walgreens c-wag-settlement-2017
  28. Patents assigned to Theranos IP Company and pledged to Fortress Credit Corp. c-wd-patent-assignment c-wd-security-interest
  29. SEC charges Theranos, Holmes and Balwani; Theranos and Holmes settle c-sec-charges c-sec-settlement
  30. Holmes and Balwani are indicted c-crim-indictment-2018
  31. Holmes steps down as CEO; David Taylor takes over c-ld-taylor-ceo
  32. Theranos assigns its assets for the benefit of creditors c-wd-general-assignment
  33. Walgreens obtains a $5,000,000 judgment in its second suit c-wag-suit-2018
  34. Labrador Diagnostics sues BioFire and bioMérieux on Theranos patents c-wd-labrador-suit c-wd-tipc-patents-2020
  35. Third superseding indictment c-crim-superseding
  36. Jury convicts Holmes on four investor counts and acquits her on four patient counts c-crim-holmes-verdict
  37. Jury convicts Balwani on all twelve counts c-crim-balwani-verdict
  38. Holmes is sentenced to 135 months c-crim-holmes-sentence
  39. Balwani is sentenced to 155 months c-crim-balwani-sentence
  40. Court orders $452,047,268 in restitution c-crim-restitution
  41. HHS-OIG excludes Holmes from federal health care programs for 90 years c-exc-holmes
  42. Final approval of the Arizona patient class settlements c-civ-arizona-settlement
  43. Ninth Circuit affirms both convictions, the sentences and the restitution order c-crim-ninth-circuit
  44. Departmental Appeals Board affirms Holmes's exclusion c-exc-holmes
  45. Holmes's sentence is reduced by one year c-crim-holmes-reduction
  46. Supreme Court denies Balwani's petition for certiorari c-crim-balwani-cert

Sources 118

  1. src-001 · Regulatory recordForm D notice of exempt offering filed by Theranos Inc (July 8, 2010) U.S. Securities and Exchange Commission (EDGAR) · 8 Jul 2010

    Items 1-16 and signature Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  2. src-002 · Court recordComplaint, SEC v. Elizabeth Holmes and Theranos, Inc., N.D. Cal. Case 5:18-cv-01602 U.S. Securities and Exchange Commission · 14 Mar 2018

    Complaint, paragraphs 1-94 and prayer Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  3. src-003 · Court recordComplaint, SEC v. Ramesh "Sunny" Balwani, N.D. Cal. Case 5:18-cv-01603 U.S. Securities and Exchange Commission · 14 Mar 2018

    Complaint Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  4. src-004 · Corporate registrySEC EDGAR submissions record for Theranos Inc (CIK 0001313697) U.S. Securities and Exchange Commission (EDGAR)

    Registrant metadata and filing index Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  5. src-005 · Regulatory recordForm D notice of exempt offering filed by Theranos Inc (May 2017) U.S. Securities and Exchange Commission (EDGAR) · 30 May 2017

    Items 1-16 and signature Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  6. src-006 · Corporate registryCorporate registry source · src-006 identified by category only · Corporate registry
  7. src-007 · Regulatory recordSEC press release 2018-41: Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud U.S. Securities and Exchange Commission · 14 Mar 2018

    Release Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  8. src-008 · MediaMedia source · src-008 identified by category only · Media
  9. src-009 · Company statementCompany statement source · src-009 identified by category only · Company statement
  10. src-010 · Regulatory recordU.S. Attorney release on the indictment of Holmes and Balwani (June 15, 2018) U.S. Attorney's Office, Northern District of California · 15 Jun 2018

    Release Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  11. src-011 · MediaMedia source · src-011 identified by category only · Media
  12. src-012 · MediaMedia source · src-012 identified by category only · Media
  13. src-013 · MediaMedia source · src-013 identified by category only · Media
  14. src-014 · Regulatory recordU.S. Attorney release on the sentencing of Ramesh Balwani (December 7, 2022) U.S. Attorney's Office, Northern District of California · 7 Dec 2022

    Release Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  15. src-015 · MediaMedia source · src-015 identified by category only · Media
  16. src-016 · Court recordAppendix to the petition for a writ of certiorari, Balwani v. United States, No. 25-1330: Ninth Circuit opinions of 2025, district court judgments and the July 28, 2020 third superseding indictment Supreme Court of the United States (docket) · 21 May 2026

    Appendices A-F Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  17. src-017 · MediaMedia source · src-017 identified by category only · Media
  18. src-018 · MediaMedia source · src-018 identified by category only · Media
  19. src-019 · MediaMedia source · src-019 identified by category only · Media
  20. src-020 · MediaMedia source · src-020 identified by category only · Media
  21. src-021 · Company statementCompany statement source · src-021 identified by category only · Company statement
  22. src-022 · MediaMedia source · src-022 identified by category only · Media
  23. src-023 · Corporate registrySEC EDGAR submissions record for Walgreen Co (CIK 0000104207) U.S. Securities and Exchange Commission (EDGAR)

    Registrant metadata Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  24. src-024 · Corporate registrySEC EDGAR submissions record for Safeway Inc (CIK 0000086144) U.S. Securities and Exchange Commission (EDGAR)

    Registrant metadata Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  25. src-025 · Corporate registrySEC EDGAR submissions record for Fortress Investment Group LLC (CIK 0001380393) U.S. Securities and Exchange Commission (EDGAR)

    Registrant metadata Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  26. src-026 · Company statementCompany statement source · src-026 identified by category only · Company statement
  27. src-027 · Company statementCompany statement source · src-027 identified by category only · Company statement
  28. src-028 · Regulatory recordRegulatory record source · src-028 identified by category only · Regulatory record
  29. src-029 · OtherLetter of members of the House Committee on Energy and Commerce to the acting CMS administrator on Theranos (July 26, 2016) U.S. House Committee on Energy and Commerce (minority members) · 26 Jul 2016

    Letter Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  30. src-030 · MediaMedia source · src-030 identified by category only · Media
  31. src-031 · Regulatory recordArizona Attorney General list of past consumer settlements (Theranos entry) Arizona Attorney General

    Theranos entry Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  32. src-032 · Court recordMemorandum opinion, Partner Investments, L.P. v. Theranos, Inc., Del. Ch. C.A. No. 12816-VCL and No. 2017-0262-JTL (April 23, 2018) Court of Chancery of the State of Delaware · 23 Apr 2018

    Memorandum opinion Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  33. src-033 · Corporate registryUSPTO assignment record, Reel/Frame 44838/0909 (Theranos Inc. to Theranos IP Company, LLC) U.S. Patent and Trademark Office · 12 Dec 2017

    Assignment record and property list Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  34. src-034 · Corporate registryUSPTO assignment records listing Theranos, Inc. as assignee U.S. Patent and Trademark Office

    Assignment records Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  35. src-035 · Corporate registryUSPTO assignment record, Reel/Frame 44839/0568 (security interest to Fortress Credit Corp.) U.S. Patent and Trademark Office · 12 Dec 2017

    Assignment record Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  36. src-036 · Regulatory recordCMS CLIA Annual Laboratory Registry 2017 Centers for Medicare & Medicaid Services · 2017

    Sanctions sections Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  37. src-037 · Regulatory recordForm D/A filed by Partner Investments L P (2014) U.S. Securities and Exchange Commission (EDGAR) · 4 Feb 2014

    Items 1-3 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  38. src-038 · ResearchResearch source · src-038 identified by category only · Research
  39. src-039 · Company statementPalo Alto Networks definitive proxy statement for fiscal 2018 U.S. Securities and Exchange Commission (EDGAR) · 2018

    Director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  40. src-040 · MediaMedia source · src-040 identified by category only · Media
  41. src-041 · Court recordReport and recommendation, Walgreen Co. v. Theranos, Inc., D. Del. C.A. No. 16-1040-RGA-MPT (July 27, 2017) U.S. District Court for the District of Delaware · 27 Jul 2017

    Report and recommendation Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  42. src-042 · MediaMedia source · src-042 identified by category only · Media
  43. src-043 · MediaMedia source · src-043 identified by category only · Media
  44. src-044 · Company statementCommerce One, Inc. Form 8-K with the CommerceBid.com merger agreement (November 1999) U.S. Securities and Exchange Commission (EDGAR) · 24 Nov 1999

    Item 5 and exhibits Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  45. src-045 · Regulatory recordRegulatory record source · src-045 identified by category only · Regulatory record
  46. src-046 · MediaMedia source · src-046 identified by category only · Media
  47. src-047 · MediaMedia source · src-047 identified by category only · Media
  48. src-048 · MediaMedia source · src-048 identified by category only · Media
  49. src-049 · MediaMedia source · src-049 identified by category only · Media
  50. src-050 · MediaMedia source · src-050 identified by category only · Media
  51. src-051 · MediaMedia source · src-051 identified by category only · Media
  52. src-052 · Court recordCourt record source · src-052 identified by category only · Court record
  53. src-053 · Regulatory recordSchedule 13D filed by Bechtel Group, Inc. and affiliates (October 2001) U.S. Securities and Exchange Commission (EDGAR) · 11 Oct 2001

    Items 2 and Schedule A Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  54. src-054 · MediaMedia source · src-054 identified by category only · Media
  55. src-055 · MediaMedia source · src-055 identified by category only · Media
  56. src-056 · MediaMedia source · src-056 identified by category only · Media
  57. src-057 · Court recordSupreme Court docket No. 25-1330, Ramesh Sunny Balwani v. United States Supreme Court of the United States (docket) · 5 Oct 2026

    Docket entries Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  58. src-058 · Court recordOrder on motions to dismiss, In re Arizona Theranos, Inc., Litigation, D. Ariz. No. 2:16-cv-2138 (April 10, 2018) U.S. District Court for the District of Arizona (GPO copy) · 10 Apr 2018

    Order Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  59. src-059 · Court recordCourt record source · src-059 identified by category only · Court record
  60. src-060 · MediaMedia source · src-060 identified by category only · Media
  61. src-061 · MediaMedia source · src-061 identified by category only · Media
  62. src-062 · Regulatory recordU.S. Attorney case page, United States v. Elizabeth A. Holmes, et al., 18-CR-00258-EJD U.S. Attorney's Office, Northern District of California · 12 Dec 2022

    Case page Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  63. src-063 · Court recordCourt record source · src-063 identified by category only · Court record
  64. src-064 · OtherOther source · src-064 identified by category only · Other
  65. src-065 · MediaMedia source · src-065 identified by category only · Media
  66. src-066 · MediaMedia source · src-066 identified by category only · Media
  67. src-067 · MediaMedia source · src-067 identified by category only · Media
  68. src-068 · MediaMedia source · src-068 identified by category only · Media
  69. src-069 · MediaMedia source · src-069 identified by category only · Media
  70. src-070 · MediaMedia source · src-070 identified by category only · Media
  71. src-071 · Regulatory recordHHS Departmental Appeals Board Decision No. 3222, Elizabeth A. Holmes (January 16, 2026) HHS Departmental Appeals Board · 16 Jan 2026

    Decision Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  72. src-072 · Regulatory recordHHS-OIG release on the exclusion of the founder and CEO of Theranos, Inc. (January 2024) HHS Office of Inspector General · 19 Jan 2024

    Release Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  73. src-073 · Court recordCourt record source · src-073 identified by category only · Court record
  74. src-074 · Court recordCourt record source · src-074 identified by category only · Court record
  75. src-075 · Court recordCourt record source · src-075 identified by category only · Court record
  76. src-076 · Company statementExhibit 21 (subsidiaries) to the Walgreen Co. annual report for fiscal 2012 U.S. Securities and Exchange Commission (EDGAR) · 2012

    Exhibit 21 Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  77. src-077 · OtherOther source · src-077 identified by category only · Other
  78. src-078 · MediaMedia source · src-078 identified by category only · Media
  79. src-079 · Regulatory recordRegulatory record source · src-079 identified by category only · Regulatory record
  80. src-080 · Court recordCourt record source · src-080 identified by category only · Court record
  81. src-081 · Company statementCompany statement source · src-081 identified by category only · Company statement
  82. src-082 · MediaMedia source · src-082 identified by category only · Media
  83. src-083 · OtherOther source · src-083 identified by category only · Other
  84. src-084 · Company statementCompany statement source · src-084 identified by category only · Company statement
  85. src-085 · OtherOther source · src-085 identified by category only · Other
  86. src-086 · Corporate registryCorporate registry source · src-086 identified by category only · Corporate registry
  87. src-087 · Company statementCompany statement source · src-087 identified by category only · Company statement
  88. src-088 · OtherOther source · src-088 identified by category only · Other
  89. src-089 · Company statementCompany statement source · src-089 identified by category only · Company statement
  90. src-090 · MediaMedia source · src-090 identified by category only · Media
  91. src-091 · MediaMedia source · src-091 identified by category only · Media
  92. src-092 · Company statementOracle Corporation definitive proxy statement (1999) U.S. Securities and Exchange Commission (EDGAR) · 1999

    Director biographies and letter Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  93. src-093 · MediaMedia source · src-093 identified by category only · Media
  94. src-094 · Company statementAt Road, Inc. definitive proxy statement (2003) U.S. Securities and Exchange Commission (EDGAR) · 2003

    Director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  95. src-095 · OtherOther source · src-095 identified by category only · Other
  96. src-096 · Corporate registryFlorida corporation record of THERANOS, INC. (F12000001870) Florida Division of Corporations

    Detail by entity name Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  97. src-097 · Company statementDolby Laboratories, Inc. definitive proxy statement (2025) U.S. Securities and Exchange Commission (EDGAR) · 2025

    Director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  98. src-098 · MediaMedia source · src-098 identified by category only · Media
  99. src-099 · OtherOffice of the Historian biography of Henry A. Kissinger U.S. Department of State, Office of the Historian

    Biography Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  100. src-100 · OtherDefense Department historical biography of William J. Perry Office of the Secretary of Defense Historical Office

    Biography Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  101. src-101 · OtherU.S. Senate featured biography of William H. Frist United States Senate

    Biography Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  102. src-102 · Company statementCompany statement source · src-102 identified by category only · Company statement
  103. src-103 · OtherOther source · src-103 identified by category only · Other
  104. src-104 · Company statementCisco Systems, Inc. definitive proxy statement (2012) U.S. Securities and Exchange Commission (EDGAR) · 2012

    Director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  105. src-105 · Company statementGeneral Dynamics Corporation definitive proxy statement (2015) U.S. Securities and Exchange Commission (EDGAR) · 2015

    Letter and director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  106. src-106 · OtherWHO in memoriam notice for Dr William H. Foege (January 25, 2026) World Health Organization · 25 Jan 2026

    News item Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  107. src-107 · OtherOther source · src-107 identified by category only · Other
  108. src-108 · OtherOther source · src-108 identified by category only · Other
  109. src-109 · OtherOther source · src-109 identified by category only · Other
  110. src-110 · Regulatory recordForm 4 filed by T. Peter Thomas for NeoPhotonics Corp (February 2011) U.S. Securities and Exchange Commission (EDGAR) · 7 Feb 2011

    Explanation of responses Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  111. src-111 · Corporate registryFlorida annual report of Theranos, Inc. for 2013 (July 30, 2013) Florida Division of Corporations · 30 Jul 2013

    Annual report Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  112. src-112 · OtherOther source · src-112 identified by category only · Other
  113. src-113 · Corporate registryFlorida annual report of Theranos, Inc. for 2014 (August 6, 2014) Florida Division of Corporations · 6 Aug 2014

    Annual report Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  114. src-114 · Company statementThe Coca-Cola Company definitive proxy statement (1997) U.S. Securities and Exchange Commission (EDGAR) · 1997

    Director biographies Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  115. src-115 · Company statementStevanato Group S.p.A. IPO prospectus, Form 424B4 (July 2021) U.S. Securities and Exchange Commission (EDGAR) · Jul 2021

    Management section Retained copy of the document in the frozen case database, read in the passages cited by the claims. Accessed 21 October 2026.

  116. src-116 · OtherOther source · src-116 identified by category only · Other
  117. src-117 · MediaMedia source · src-117 identified by category only · Media
  118. src-118 · MediaMedia source · src-118 identified by category only · Media

cite this dossier

DossierTwist, “Theranos, Inc.: leadership, investors, partners and proceedings, 2003–2026”, dt.040, 26 October 2026, https://dossiertwist.com/dossiers/theranos-inc/

Free to read, cite and republish with credit under CC BY 4.0: credit “DossierTwist” and link to the dossier.

Data: JSON, CSV and the network graph.

share

We listen to all sides: responses are shown next to the claims they answer. To send a correction or a reply, write to dossiertwist@proton.me.